DOCSLIB.ORG

Impact of Synbiotics on Gut Microbiota During Early Life

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Impact of Synbiotics on Gut Microbiota During Early Life www.nature.com/scientificreports OPEN Impact of synbiotics on gut microbiota during early life: a randomized, double‑blind study Nopaorn Phavichitr1, Shugui Wang3, Sirinuch Chomto4, Ruangvith Tantibhaedhyangkul1, Alexia Kakourou2, Sukkrawan Intarakhao5, Sungkom Jongpiputvanich5, COLOR Study Group2*, Guus Roeselers2* & Jan Knol2,6 Human milk is considered the optimal nutrition for infants and found to contain signifcant numbers of viable bacteria. The aim of the study was to assess the efects of a specifc synbiotic combination at doses closer to the bacterial cells present in human milk, on intestinal bifdobacteria proportions (relative abundance), reduction of potential pathogens and gut physiological conditions. A clinical study was conducted in 290 healthy infants aged from 6 to 19 weeks. Infants received either a control infant formula or one of the two investigational infant formulas (control formula with 0.8 g/100 ml scGOS/lcFOS and Bifdobacterium breve M‑16V at either 1 × 104 cfu/ml or 1 × 106 cfu/ml). Exclusively breastfed infants were included as a reference. Analyses were performed on intention‑ to‑treat groups and all‑subjects‑treated groups. After 6 weeks of intervention, the synbiotics at two diferent doses signifcantly increased the bifdobacteria proportions in healthy infants. The synbiotic supplementation also decreased the prevalence (infants with detectable levels) and the abundance of C. difcile. Closer to the levels in the breastfed reference group, fecal pH was signifcantly lower while l‑lactate concentrations and acetate proportions were signifcantly higher in the synbiotic groups. All formulas were well tolerated and all groups showed a comparable safety profle based on the number and severity of adverse events and growth. In healthy infants, supplementation of infant‑type bifdobacterial strain B. breve M‑16V, at a dose close to bacterial numbers found in human milk, with scGOS/lcFOS (9:1) created a gut environment closer to the breastfed reference group. This specifc synbiotic mixture may also support gut microbiota resilience during early life. Clinical Trial Registration This clinical study named Color Synbiotics Study, was registered in ClinicalTrials.gov on 18 March 2013. Registration number is NCT01813175. https ://clini caltr ials.gov/ ct2/show/NCT01 81317 5. Abbreviations EPEC Enteropathogenic Escherichia coli EAEC Enteroaggregative Escherichia coli HMOs Human milk oligosaccharides scGOS/lcFOS Short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides CFU Colony forming unit Syn4 Control formula supplemented with 0.8 g/100 ml scGOS/lcFOS and B. breve M-16V at a dose of 1 × 104 cfu/ml Syn6 Control formula supplemented with 0.8 g/100 ml scGOS/lcFOS and B. breve M-16V at a dose of 1 × 106 cfu/ml FISH Fluorescent in situ hybridization SCFA Short chain fatty acid ITT Intention-to-treat AST All-subjects-treated 1Department of Paediatrics, Phramongkutklao Hospital, Bangkok, Thailand. 2Danone Nutricia Research, Utrecht, The Netherlands. 3Danone Nutricia Research, Singapore, Singapore. 4Nutritional Unit, Department of Pediatrics, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand. 5Department of Pediatrics, Thammasat Hospital, Faculty of Medicine, Thammasat University, Bangkok, Thailand. 6Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands. *A list of authors and their afliations appears at the end of the paper. *email: [email protected] Scientifc Reports | (2021) 11:3534 | https://doi.org/10.1038/s41598-021-83009-2 1 Vol.:(0123456789) www.nature.com/scientificreports/ MMRM Mixed-efect model for repeated measures ANCOVA Analysis of covariance GLMM Generalized linear mixed model RDA Redundancy analysis TRT​ Treatment WHO World Health Organization In early life, the infant’s gut microbiota of healthy breastfed infants is normally dominated by infant-type bif- dobacteria such as Bifdobacterium breve, Bifdobacterium bifdum and Bifdobacterium longum subsp. infantis. Tese members of the gut microbiota make the infant gut more resistant to pathogen colonization1, improve certain vaccination responses 2, support immune maturation and support gut barrier development 3. However, not all infants’ gut microbiotas are dominated by Bifdobacterium species and some are even devoid of them4,5. Environmental factors such as mode of delivery, antibiotics and feeding patterns infuence bifdobacterial colo- nization of the infant’s gut. Given the major role of infant-type bifdobacteria in structuring the gut microbiome in early life, it is important to support the colonization by relevant Bifdobacterium species6. Opportunistic pathogens such as Clostridium difcile, Clostridium perfringens, enteropathogenic Escherichia coli (EPEC) and enteroaggregative Escherichia coli (EAEC) are ofen found in infants’ guts. C. difcile colonizes 10–70% of infants below 1 year of age 7. C. difcile infections during infancy may not only cause diarrhoea but are also associated with higher risk of allergic diseases during early life8. Breastfeeding, known to reduce the prevalence of C. difcile in infants compared to formula feeding (14% vs 30%, respectively)9, also helps in pre- vention of infections and allergic diseases during early life10,9. Human milk is considered the optimal nutrition for infants and contains a signifcant number of viable bacteria, which are an important source for vertical microbial transmission from mother to infant11–13. If this colonization route is disrupted, early life microbiota development may be impaired. Human milk is estimated to contain about 103–105 bacterial cells/ml based on fow cytometry and quantitative polymerase chain reaction (q-PCR) methods12,14–18. Te human milk microbiota is a taxonomically diverse com- munity, to which, bifdobacteria contribute up to 104 cells/ml17,19. B. breve is the most commonly isolated infant- type Bifdobacterium species from human milk 20. It is one of the dominant members of the infant’s gut micro- biota, involved in the metabolism of human milk oligosaccharides (HMOs) and the production of vitamins21,22. Non-infant-type bifdobacteria such as B. animalis subsp. lactis, isolated from diverse mammalian hosts, and B. adolescentis, normally found in the adult human gut, are genetically less equipped to metabolize HMOs 22. Synbiotics, a combination of probiotics and prebiotics that confers health benefts to the host 23,24, ofer an efcient way to mimic milk driven colonisation and formation of a Bifdobacterium dominated ecosystem in the infant gut25. Synbiotics containing short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides (scGOS/lcFOS) with a 9:1 ratio and B. breve M-16V, has been shown to restore the delayed bifdobacteria colo- nization in caesarean section (C-section) born infants25 and to improve the symptoms of IgE-associated atopic dermatitis26. In addition, there is long and comprehensive tolerance and safety track record for the use of B. breve M-16V as a probiotic for infants, including infants with a very low birth weight. Te efects of probiotics or synbiotics are dose and strain dependent. Te doses of probiotics and synbiotic used in previous studies in infants and children range from 108 to 1011 cfu/day27. As human milk contains relatively low numbers of viable bacteria (ranging from 10 3 to 10 5 cfu cfu/ml, about 106–108 cfu/day)12, it is important to understand the efects of diferent doses of synbiotics on the infant’s gut microbiota. Te primary objective of this study was to evaluate the bifdogenic efect of an infant formula containing synbiotics with two doses of B. breve M-16V (either 1 × 104 cfu/ml or 1 × 106 cfu/ml), in combination with scGOS/ lcFOS (9:1) in healthy infants aged 6–19 weeks. Te study also explored the efects of this specifc synbiotics on pathogen reduction and gut physiological conditions in early life. Patients and methods Tis was an exploratory, randomized, double-blind, controlled study conducted between May 2013 and Septem- ber 2015 in Tailand. Te protocol and all accompanying material provided to the subjects, such as information sheets or description of the study used to obtain informed consent, were submitted to the following ethics review committees: Institutional Review Board, Chulalongkorn University; Institutional Ethics Review Committee, Royal Tai Army Medical Department; Human Research Ethics Committee, Tammasat University. Approval from the three Ethics Committees was obtained before start of the study, and was documented in a letter to the investigators specifying the date on which the committee met and granted the approval. Written informed consent was obtained from all parents/caregivers before inclusion in the study. Te study was registered in ClinicalTrials.gov (March 18, 2013; #NCT01813175). Te study was conducted according to ICH-GCP principles, and in compliance with the principles of the ‘Declaration of Helsinki’ (59th WMA General Assembly, Seoul, October 2008) and with the Tai laws and regulations. Inclusion criteria were a gestational age between 37 and 42 weeks, infant age 43–65 days, and exclusive formula feeding for at least 1 week (except for the breastfed reference group). Exclusion criteria were, malnutrition, weaned before inclusion, malformations, use of systemic antibiotics or anti-mycotic drugs within 4 weeks prior to study entry, gastroenteritis or diarrhoea in the last 2 weeks prior to study entry. Sample size calculation methods and randomisation and unblinding procedures are reported in detail in the
Load more

Recommended publications
  • Utilization of Synbiotics, Acidifiers, and a Polyanhydride Nanoparticle
    Utilization of Synbiotics, Acidifiers, and a Polyanhydride Nanoparticle Vaccine in Enhancing the Anti-Salmonella Immune Response in Laying Hens Post-Salmonella Challenge Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Ashley D. Markazi, M.S. Graduate Program in Animal Sciences The Ohio State University 2018 Dissertation Committee: Ramesh K. Selvaraj, Advisor Michael S. Lilburn, Co-Advisor Renukaradhya Gourapura Lisa Bielke Copyright by Ashley D. Markazi 2018 ABSTRACT Salmonellosis, a zoonotic disease caused by the bacterium Salmonella, is most commonly attributed to the consumption of poultry eggs and meat. The current project examined the effects of drinking water synbiotics, in-feed acidifiers, and a polyanhydride nanoparticle Salmonella vaccine in enhancing the anti-Salmonella immune response and decreasing Salmonella infection in laying hens. The synbiotic experiment was conducted to study the effects of drinking water supplementation of synbiotic product in laying hens with and without a Salmonella challenge. A total of 384 one-day-old layer chicks were randomly distributed to the drinking water synbiotic supplementation or control groups. At 14 wk of age, the birds were vaccinated with a Salmonella vaccine, resulting in a 2 (control and synbiotic) X 2 (non-vaccinated and vaccinated) factorial arrangement of treatments. At 24 wk of age, half of the birds in the vaccinated groups and all the birds that were not vaccinated were challenged with Salmonella Enterica serotype Enteritidis, resulting in a 3 (vaccinated, challenged, vaccinated+challenged) X 2 (control and synbiotic) factorial arrangement. At 8 d post-Salmonella challenge, synbiotic supplementation decreased (P = 0.04) cecal S.
    [Show full text]
  • The International Scientific Association for Probiotics and Prebiotics (ISAPP) Consensus Statement on the Definition and Scope of Synbiotics
    CONSENSUS STATEMENT OPEN The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics Kelly S. Swanson 1 ✉ , Glenn R. Gibson 2, Robert Hutkins3, Raylene A. Reimer 4, Gregor Reid 5, Kristin Verbeke 6,7, Karen P. Scott 8, Hannah D. Holscher 9, Meghan B. Azad 10, Nathalie M. Delzenne 11 and Mary Ellen Sanders 12 Abstract | In May 2019, the International Scientific Association for Probiotics and Prebiotics (ISAPP) convened a panel of nutritionists, physiologists and microbiologists to review the definition and scope of synbiotics. The panel updated the definition of a synbiotic to “a mixture comprising live microorganisms and substrate(s) selectively utilized by host microorganisms that confers a health benefit on the host”. The panel concluded that defining synbiotics as simply a mixture of probiotics and prebiotics could suppress the innovation of synbiotics that are designed to function cooperatively. Requiring that each component must meet the evidence and dose requirements for probiotics and prebiotics individually could also present an obstacle. Rather, the panel clarified that a complementary synbiotic, which has not been designed so that its component parts function cooperatively, must be composed of a probiotic plus a prebiotic, whereas a synergistic synbiotic does not need to be so. A synergistic synbiotic is a synbiotic for which the substrate is designed to be selectively utilized by the co-administered microorganisms. This Consensus Statement further explores the levels of evidence (existing and required), safety, effects upon targets and implications for stakeholders of the synbiotic concept. Notable properties of the gut microbiota include its itself was formed from the Greek prefix ‘syn’, meaning functionality and resilience1.
    [Show full text]
  • PROMITOR® Soluble Fibre and Synbiotics
    PROMITOR® Soluble Fibre and Synbiotics Recent consensus statement released by The International Scientific Association for Probiotics and Prebiotics (ISAPP) provides a definition and scope of synbiotics.1 • Association of academic and industrial scientists with a common interest in generating high-quality, collaborative, multidisciplinary science and guidance • Only scientific organization dedicated specifically to probiotics and prebiotics • Provides an objective, science-based, trusted voice to guide informed choices PREBIOTICS PROBIOTICS A substrate that is selectively utilized Live microorganisms that, when by host microorganisms conferring a administered in adequate amounts, health benefit confer a health benefit on the host SYNBIOTIC Mix of live microorganisms and substrate(s) selectively utilized by host microorganisms for a health benefit Human clinical study evaluates combination of prebiotic PROMITOR® Soluble Fibre and probiotic Lactobacillus rhamnosus, LGG® PROMITOR® Probiotic Health Soluble Fibre + LGG = Synbiotic Benefit(s) Human intervention study with healthy elderly adults (aged 60-80), consumed 12 g/day of PROMITOR® soluble fibre with or without L. rhamnosus GG® for three weeks.2 i. All treatments (fibre alone or with probiotics) provided significant changes in gut microbiota, while a placebo did not ii. Consumption of L. rhamnosus GG® combined with PROMITOR® soluble fibre increased NK cell activity, a marker of innate immunity, compared to baseline in females and the older group iii. In addition, the study showed a decrease of the pro-inflammatory cytokine IL-6 with the dietary intervention of L. rhamnosus GG® combined with PROMITOR® soluble fibre © Tate&Lyle 2021 PROMITOR® Soluble Fibre Overview PROMITOR® Soluble Fibre makes it easy to meet consumer demands for more fibre.
    [Show full text]
  • Synbiotics Reduce Infectious Complications by Improving the Intestinal Milieu and Enhancing the Immune Function in Critically Ill Emergency Surgical Patients
    Original Contribution Kitasato Med J 2013; 43: 17-25 Synbiotics reduce infectious complications by improving the intestinal milieu and enhancing the immune function in critically ill emergency surgical patients Yuichi Kataoka,1 Tomomichi Kan'o,1 Takashi Asahara,2 Koji Nomoto,2 Kazui Soma1 1 Department of Emergency and Critical Care Medicine, Kitasato University School Medicine 2 Yakult Central Institute for Microbiological Research Objective: To determine the effects of synbiotics upon the intestinal milieu, immune response, and infection in critically ill patients. Methods: Thirty-two critically ill patients, who had undergone emergency surgery, were divided into two groups, those who started receiving enteral synbiotics (Lactobacillus casei strain Shirota and Bifidobacterium breve strain Yakult plus galactooligosaccharides; group S, n = 20) and those who did not receive enteral synbiotics (the control, group C, n = 12) within 48 hours of admission to the ICU and continuing for 14 days. Results: Baseline values were comparable between the two groups. NK (natural killer) cell activity and lymphocyte counts significantly increased in group S. C-reactive protein concentrations significantly decreased in both groups. White blood cell counts significantly decreased in group S, but remained unchanged in group C. Group S had more Bifidobacterium and Lactobacillus and less Pseudomonas than group C in the stool samples after the trial. Concentrations of fecal organic, acetic, and propionic acids were significantly greater and the incidences of infectious complications were significantly lower in group S (25% vs. 75%, P < 0.01). The ICU stay was significantly shorter for group S. None of the patients died or developed adverse events. Conclusions: Synbiotics enhanced host immune function in critically ill emergency surgical patients, improved the intestinal milieu, and decreased the incidence of infectious complications.
    [Show full text]
  • Galactooligosaccharide and Mannanoligosaccharide with Or
    Received: 20 October 2016 | Accepted: 31 January 2017 DOI: 10.1111/anu.12553 ORIGINAL ARTICLE Effect of in vitro selected synbiotics (galactooligosaccharide and mannanoligosaccharide with or without Enterococcus faecalis) on growth performance, immune responses and intestinal microbiota of juvenile narrow clawed crayfish, Astacus leptodactylus leptodactylus Eschscholtz, 1823 O. Safari1 | M. Paolucci2 1Department of Fisheries, Faculty of Natural Resources and Environment, Ferdowsi Abstract University of Mashhad, Mashhad, Iran The aim of this study was to determine the best synbiotic combination (based on 2 Department of Sciences and growth and short- chain fatty acids production) between Enterococcus faecalis and Technologies, University of Sannio, Benevento, Italy eight prebiotics. Based on the results of in vitro studies, E. faecalis + galactooligosac- charide (EGOS) and E. faecalis + mannanoligosaccharide (EMOS) were selected as Correspondence Omid Safari, Department of Fisheries, Faculty synbiotics. A 126- day feeding trial was conducted to compare the effects of prebi- of Natural Resources and Environment, otics, probiotic and synbiotics on the growth indices, In vivo ADC of nutrients, di- Ferdowsi University of Mashhad, Mashhad, Iran. gestive enzymes, hemolymph indices and finally, biological responses against 48- hr Email: [email protected] Aeromonas hydrophila exposure challenges of juvenile (4.13 ± 0.12 g) crayfish. The −1 −1 Funding information highest values of SGR (2.19% body weight day ), VFI (2.75% body weight day ), Research & Technology Deputy of Ferdowsi survival rate (96.67%) and the lowest FCR (2.33) were observed in the juvenile cray- University of Mashhad, Grant/Award Number: 39595 fish fed the EGOS-­ diet. The significantly (p < .05) highest means of in vivo ADCOM, in vivo ADCCP, in vivo ADCCF and in vivo ADCGE were measured in crayfish fed the EGOS-­ diet.
    [Show full text]
  • Review Synbiotics“ Combinationof Probiotics and Prebiotics ”
    IOSR Journal of Biotechnology and Biochemistry (IOSR-JBB) ISSN: 2455-264X, Volume 3, Issue 4 (Jul. – Aug. 2017), PP 19-24 www.iosrjournals.org Review Synbiotics“ Combinationof Probiotics And Prebiotics ” *Pavitra Sharma 1, Anuradha Singh2 ,and NupurMathur3. Environmental Microbiology Lab.Department of Zoology, University of Rajasthan, Jaipur-302004, Rajasthan (India) Research Scholar- University of Rajasthan1 Associate Professor - University of Rajasthan2 Associate Professor - University of Rajasthan3 Corresponding Author: Pavitra Sharma Abstract: The principal role offood in a body is to supply required nutrients which provides energy to sustain for physiologicalfunctions and well being. All food typesare functional, consumption of such functional food provides bioactive molecules.Probiotics, prebiotics and synbioticsare importantbioactive components of functional food which have significant role on well being of human and animal.These bioactive components provides one of the possible approach for improving the health image and developing functional products. Discovery of new prebiotic/probiotic/synbiotic functional foods leads to the food industry to renew constantly by introduction of food items with enhanced nutritional value and also with health advantage for consumers. This review provides information regarding healthbenefits of synbiotic food compounds as they provide bioactive componentsfor health. ----------------------------------------------------------------------------------------------------------------------------- ----------
    [Show full text]
  • PROMITOR® Soluble Fibre and Synbiotics PROBIOTICS
    PROMITOR® Soluble Fibre and Synbiotics Recent consensus statement released by The International Scientific Association for Probiotics and Prebiotics (ISAPP) provides a definition and scope of synbiotics.1 • Association of academic and industrial scientists with a common interest in generating high-quality, collaborative, multidisciplinary science and guidance • Only scientific organization dedicated specifically to probiotics and prebiotics • Provides an objective, science-based, trusted voice to guide informed choices PREBIOTICS PROBIOTICS A substrate that is selectively utilized Live microorganisms that, when by host microorganisms conferring a administered in adequate amounts, health benefit confer a health benefit on the host SYNBIOTIC Mix of live microorganisms and substrate(s) selectively utilized by host microorganisms for a health benefit Human clinical study evaluates combination of prebiotic PROMITOR® Soluble Fibre and probiotic Lactobacillus rhamnosus, LGG® PROMITOR® Probiotic Health Soluble Fibre + LGG = Synbiotic Benefit(s) Soluble Fibre Human intervention study with healthy elderly adults (aged 60-80), consumed 12 g/day of PROMITOR® soluble fibre with or without L. rhamnosus GG® for three weeks.2 i. All treatments (fibre alone or with probiotics) provided significant changes in gut microbiota, while a placebo did not ii. Consumption of L. rhamnosus GG® combined with PROMITOR® soluble fibre increased NK cell activity, a marker of innate immunity, compared to baseline in females and the older group iii. In addition, the study showed a decrease of the pro-inflammatory cytokine IL-6 with the dietary intervention of L. rhamnosus GG® combined with PROMITOR® soluble fibre © Tate&Lyle 2021 PROMITOR® Soluble Fibre Overview PROMITOR® Soluble Fibre makes it easy to meet consumer demands for more fibre.
    [Show full text]
  • A Closer Look at Synbiotics a Powerful Combination of Prebiotics and Probiotics
    NUTRITION EXCHANGE A Closer Look at Synbiotics A Powerful Combination of Prebiotics and Probiotics When it comes to the gut microbiota, sometimes it’s not only Prebiotics, such as psyllium, are non-digestible carbohydrates what you are feeding a patient, but also how bacteria and certain that are selectively fermented by beneficial bacteria in the ingredients can work together in a beneficial way.Synbiotics colon. Prebiotics may promote growth and metabolic activity of are a mixture of prebiotics and probiotics that benefit the host beneficial bacterial species.1,2 This may improve microbial balance by improving the survival and implantation of live beneficial in the gastrointestinal (GI) tract and promote production of bacteria in the gastrointestinal tract.1,2 This is achieved by butyrate, the primary fuel source for colonocytes.2,3 selectively stimulating the growth of beneficial bacteria to help Butyrate, the short-chain fatty acid, may confer the following maintain gut health.1,3 GI benefits:2,6,7 2,5 The World Health Organization definesprobiotics as “live • Increase absorption of water and electrolytes microorganisms that when consumed in adequate amounts • Enhance mucosal blood flow confer a health benefit on the host.”4 • Nourish gut epithelium to promote cell turnover • Modification of gut microbiota • Enhance mucosal size and stability through increasing • Compete with pathogenic bacteria for binding to gut mucosa microvilli size • Strengthening of gut epithelial barrier • Reduce microbial adhesion of pathogenic bacteria • Modulation of host immune system • Anti-inflammatory action to increase healing after an insult • Production of short-chain fatty acids and decrease gut permeability • Enhance immune system function The health benefits of probiotics are strain specific.
    [Show full text]
  • Probiotics, Prebiotics and Synbiotics—A Promising Strategy in Prevention and Treatment of Cardiovascular Diseases?
    International Journal of Molecular Sciences Review Probiotics, Prebiotics and Synbiotics—A Promising Strategy in Prevention and Treatment of Cardiovascular Diseases? Beata Olas Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/3, 90-236 Lodz, Poland; [email protected]; Tel./Fax: +48-42-635-4484 Received: 19 November 2020; Accepted: 17 December 2020; Published: 20 December 2020 Abstract: Recent evidence suggests that probiotics, prebiotics and synbiotics may serve as important dietary components in the prevention (especially) and treatment of cardiovascular diseases (CVD), but the recommendations for their use are often based on brief reports and small clinical studies. This review evaluates the current literature on the correlation between CVD and probiotics, prebiotics and synbiotics. Although research on probiotics, prebiotics and synbiotics has grown exponentially in recent years, particularly regarding the effect of probiotics on CVD, their mechanisms have not been clearly defined. It has been proposed that probiotics lower cholesterol levels, and may protect against CVD, by increasing bile salt synthesis and bile acid deconjugation. Similar effects have also been observed for prebiotics and synbiotics; however, probiotics also appear to have anti-oxidative, anti-platelet and anti-inflammatory properties. Importantly, probiotics not only have demonstrated effects in vitro and in animal models, but also in humans, where supplementation with probiotics decreases
    [Show full text]
  • Synbiotic Preparation with Lactic Acid Bacteria and Inulin As A
    a ISSN 0101-2061 Food Science and Technology DDOI http://dx.doi.org/10.1590/1678-457X.26216 Synbiotic preparation with Lactic acid bacteria and inulin as a functional food: In vivo evaluation of microbial activities, and preneoplastic aberrant crypt foci Chaiyavat CHAIYASUT1, Thanawat PATTANANANDECHA1, Sasithorn SIRILUN1, Prasit SUWANNALERT2, Sartjin PEERAJAN3, Bhagavathi Sundaram SIVAMARUTHI1* Abstract Host microbiome and metabolome are associated with the incidence of colorectal cancer (CC), one of the major health problems in developed countries. The pro and prebiotic supplementation helps to improve the host health. Inulin is one such prebiotic used for the enhancement of naïve probiotic bacterial population. This paper explains the impact of inulin (PRE) extracted from Jerusalem artichoke (JA), Lactobacillus plantarum HII11 (PRD), and synbiotic (SYN; inulin + L. plantarum HII11) preparation on Azoxymethane mediated CC induced rat model with respect to changes in microbial load, microbial enzymes, and preneoplastic aberrant crypt foci. The results suggested that the PRE and SYN supplementation effectively reduced the selected pathogenic bacteria (Salmonella spp., and Escherichia coli), microbial enzymes and increased the probiotic load. The intervention of SYN significantly reduced the colonic ACF in CC model. The study results revealed that the supplementation of SYN diet (inulin and L. plantarum HII11) protects the ADM-mediated colon cancer induced host. Keywords: inulin; L. plantarum; probiotic; prebiotic; synbiotic. Practical Application: The study results help to develop functional food to improve the human health. 1 Introduction Colorectal cancer (CC) is one of the major health problems the growth and/ or activity of probiotic bacteria, resisting with the vast incidence in developed countries.
    [Show full text]
  • Prebiotics and Synbiotics: Dietary Strategies for Improving Gut Health Janina A
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Faculty Publications in Food Science and Food Science and Technology Department Technology 2016 Prebiotics and synbiotics: Dietary strategies for improving gut health Janina A. Krumbeck University of Nebraska-Lincoln, [email protected] Maria X. Maldonado-Gomez University of Nebraska – Lincoln, [email protected] Amanda E. Ramer-Tait University of Nebraska-Lincoln, [email protected] Robert W. Hutkins University of Nebraska-Lincoln, [email protected] Follow this and additional works at: http://digitalcommons.unl.edu/foodsciefacpub Part of the Food Microbiology Commons Krumbeck, Janina A.; Maldonado-Gomez, Maria X.; Ramer-Tait, Amanda E.; and Hutkins, Robert W., "Prebiotics and synbiotics: Dietary strategies for improving gut health" (2016). Faculty Publications in Food Science and Technology. 232. http://digitalcommons.unl.edu/foodsciefacpub/232 This Article is brought to you for free and open access by the Food Science and Technology Department at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Publications in Food Science and Technology by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Published in Current Opinion in Gastroenterology 32 (2016), pp. 110–119. doi:10.1097/MOG.0000000000000249 Copyright © 2016 Wolters Kluwer Health, Inc. Used by permission. digitalcommons.unl.edu Prebiotics and synbiotics: Dietary strategies for improving gut health Janina A. Krumbeck,1, 2 Maria X. Maldonado-Gomez,1 Amanda E. Ramer-Tait,1 and Robert W. Hutkins1 1 Department of Food Science and Technology, University of Nebraska–Lincoln, Lincoln, Nebraska, USA 2 School of Biological Sciences, University of Nebraska–Lincoln, Lincoln, Nebraska, USA Corresponding author — Robert W.
    [Show full text]
  • Gut Microbiota and Probiotics/Synbiotics for Modulation of Immunity in Critically Ill Patients
    nutrients Review Gut Microbiota and Probiotics/Synbiotics for Modulation of Immunity in Critically Ill Patients Kentaro Shimizu * , Masahiro Ojima and Hiroshi Ogura Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; [email protected] (M.O.); [email protected] (H.O.) * Correspondence: [email protected] Abstract: Patients suffering from critical illness have host inflammatory responses against injuries, such as infection and trauma, that can lead to tissue damage, organ failure, and death. Modulation of host immune response as well as infection and damage control are detrimental factors in the management of systemic inflammation. The gut is the motor of multiple organ failure following injury, and it is recognized that gut dysfunction is one of the causative factors of disease progression. The gut microbiota has a role in maintaining host immunity, and disruption of the gut microbiota might induce an immunosuppressive condition in critically ill patients. Treatment with probiotics and synbiotics has been reported to attenuate systemic inflammation by maintaining gut microbiota and to reduce postoperative infectious complications and ventilator-associated pneumonia. The administration of prophylactic probiotics/synbiotics could be an important treatment option for preventing infectious complications and modulating immunity. Further basic and clinical research is needed to promote intestinal therapies for critically ill patients. Citation: Shimizu, K.; Ojima, M.; Keywords: microbiota; gut; ICU; immune; ventilator; inflammation; probiotics; prebiotics; Ogura, H. Gut Microbiota and synbiotics; critically Probiotics/Synbiotics for Modulation of Immunity in Critically Ill Patients. Nutrients 2021, 13, 2439.
    [Show full text]